2020•国际医药卫生导报Requires access
Effect of intravenous thrombolysis with Ureklin and rt-PA on NIHSS score and quality of life in patients with acute cerebral infarction beyond thrombolysis time window
Haoqin Lu
Open publisher page 0 citations
Abstract
Objective
To investigate the effect of intravenous thrombolysis with Ureklin and recombinant tissue plasminogen activator (rt-PA) on the degree of neurological deficit (NIHSS) and quality of life in patients with acute cerebral infarction beyond thrombolysis time window.
Methods
86 patients with acute cerebral infarction who exceeded the time of thrombolysis were enrolled in our hospital from September, 2015 to August, 2018. They were divided into a control group and an observation group according the treatment schemes, with 43 cases in each group. The control group received routine treatment, and the observation group was treated by intravenous thrombolysis with Ureklin and rt-PA. The incidences of adverse reactions, the NIHSS scores before and 1, 7, and 21 days after the treatment, and the quality of life (GQOLI-74) scale before and 6 months after the treatment were statistically compared.
Results
There was no statistical difference in the NIHSS score between these two groups before the treatment (P>0.05). 1, 7, and 21 days after the treatment, the NIHSS scores of the observation group were (10.56±2.98), (6.30±2.58), and (4.95±1.76), which were lower than those of the control group (all P 0.05). 6 months after the treatment, the scores of body, psychological, social, and material functions were (68.69±6.87), (70.36±7.63), (70.26±7.81), and (71.13±7.58) in the observation group, which were higher those in the control group (all P<0.05).
Conclusion
Intravenous thrombolysis with Ureklin and rt-PA for patients with acute cerebral infarction beyond the time of thrombolysis can promote the recovery of neurological deficits and improve their quality of life without increasing the incidence of adverse reactions. It is worthy of clinical promotion and application
Key words:
Acute cerebral infarction; Recombinant tissue plasminogen activator; Intravenous thrombolysis; Ureklin